{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T07:01:28Z","timestamp":1648969288460},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.diagmicrobio.2018.06.020","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T12:49:32Z","timestamp":1530190172000},"page":"332-337","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Different formulations of vancomycin: In vitro antimicrobial activity against clinical isolates of methicillin-resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"92","author":[{"given":"Franciele Viana","family":"Fabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayara Assump\u00e7\u00e3o","family":"Lolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Gimenes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina Bronharo","family":"Tognim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvana Martins","family":"Caparroz-Assef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2012.07.005","article-title":"Risk factors for anti-MRSA drug resistance","volume":"40","author":"Abe","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.06.020_bb0010","author":"ANVISA\/Minist\u00e9rio da Sa\u00fade"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.mjafi.2013.11.008","article-title":"In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus","volume":"70","author":"Chaudhari","year":"2014","journal-title":"Med J Armed Forces India"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0025","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jac\/dkt340","article-title":"Method-specific performance of vancomycin MIC susceptibility tests in predicting mortality of patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"69","author":"Chen","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.06.020_bb0030","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2018.06.020_bb0035","series-title":"M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2018.06.020_bb0040","author":"European Committee on Antimicrobial Susceptibility Testing (EUCAST)"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0045","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/AAC.00164-12","article-title":"Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays","volume":"56","author":"Hadwiger","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0050","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/cid\/cir935","article-title":"The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis","volume":"54","author":"van Hal","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0055","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jinf.2016.12.007","article-title":"Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not supportswitching antimicrobials","volume":"74","author":"Hos","year":"2017","journal-title":"J Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0060","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10096-012-1811-7","article-title":"Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC","volume":"32","author":"Khatib","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0065","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1128\/JCM.02215-10","article-title":"Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus","volume":"49","author":"Kruzel","year":"2011","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0070","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jmii.2013.10.008","article-title":"Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010","volume":"48","author":"Lai","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/jac\/dkt308","article-title":"Determining accurate vancomycin MIC values for methicillin-resistant Staphylococcus aureus by the microdilution method","volume":"69","author":"Lepe","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0080","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0085","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/AAC.03710-14","article-title":"Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States","volume":"59","author":"Louie","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0090","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhin.2010.05.015","article-title":"Vancomycin minimal inhibitory concentration from broth microdilution and Etest in respiratory tract samples of patients with ventilation-associated pneumonia","volume":"76","author":"Machado","year":"2010","journal-title":"J Hosp Infect"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0095","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/AAC.05344-11","article-title":"Product quality of parenteral vancomycin products in the United States","volume":"56","author":"Nambiar","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0100","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/JCM.01182-10","article-title":"Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods","volume":"48","author":"Paiva","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0105","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1128\/JCM.00448-13","article-title":"Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods","volume":"51","author":"Rybak","year":"2013","journal-title":"J Clin Microbiol"},{"issue":"7","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0110","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.00093-09","article-title":"Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1128\/AAC.01669-12","article-title":"Comparison of six generic vancomycin products for treatment of methicillin-resistant Staphylococcus aureus experimental endocarditis in rabbits","volume":"57","author":"Tattevin","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.06.020_bb0125","series-title":"The United States pharmacopeia 34-the national formulary 29","author":"United States Pharmacopeial Convention (USP)","year":"2011"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0130","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.01044-09","article-title":"Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator","volume":"54","author":"Vesga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2018.06.020_bb0135","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijantimicag.2012.04.003","article-title":"High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia","volume":"40","author":"Wi","year":"2012","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318302190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318302190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T23:22:50Z","timestamp":1542064970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318302190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0732889318302190"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.06.020","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different formulations of vancomycin: In vitro antimicrobial activity against clinical isolates of methicillin-resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}